The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran-Reference-Cited by-同舟云学术

The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran

Published:2024-08-08 Issue: Volume: Page:1-10
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Darvishi Ali¹²,Abdi Dezfouli Ramin¹,Ghasemian Zohreh³,Akbari Sari Ali³,Harirchian Mohammad Hossein⁴,Daroudi Rajabali²³

Affiliation:

1. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

2. National Center for Health Insurance Research, Tehran, Iran

3. Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

4. Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Funder

National Center for Health Insurance Research

Ethics Committee of Tehran University of Medical Sciences

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2388818

Reference59 articles.

1. Multiple sclerosis – a review

2. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

3. Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999–2018

4. Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis

5. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review